Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Maeda, Hitoshi; Kubota, Akira; Kanamori, Akira; Tanaka, Yasushi; Terauchi, Yasuo; Matsuba, Ikuro

doi:10.1016/j.diabres.2015.03.008

Cited by 13 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, urinary albumin was decreased significantly at month 9 in the < 65 years of age group, whereas there was no significant change in the other two groups, indicating that effects on the kidney are limited. Besides the 1-year follow-up in the present study, the long-term analysis of the ASSET-K study described above showed no significant change in creatinine between 6 months and 2 years after the start of treatment [11]. Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study showed that change in eGFR was -4.0 ± 18.4 mL/min/1.73 m 2 at 4 years after the start of treatment [12], also indicating that long-term therapy with sitagliptin can be considered not to induce excessive decrease in the glomerular filtration rate.…”

Section: Efficacy Of Sitagliptin In Elderly Patientssupporting

confidence: 52%

Evaluation of Age-Specific Efficacy and Safety of 12 Months of Sitagliptin Therapy Administered by Non-Diabetologists

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background:The mean age of overall incident dialysis patients is 68.9 years for men and 71.4 years for women, and it is increasing yearly, and diabetic nephropathy is the most common underlying disease of it. On the other hand, the number of diabetologist has been insufficient for an ever-increasing number of diabetic patients in Japan. In this context, the examination and treatment of diabetes in non-specialist settings, as well as in specialist settings, have become important.Methods: A multicenter, retrospective, observational study was conducted in Kanagawa, Japan. Laboratory data were compiled for 1 year at intervals of 3 months following the start of sitagliptin treatment. The subjects were divided into three groups by age: < 65 years (n = 148), 65 -74 years (n = 134), and ≥ 75 years (n = 127). Laboratory values in comparison with baseline were compared within groups at various time points, and changes from baseline were compared among the different groups. Participating doctors were not diabetologists. Results:In the 65 -74 and ≥ 75 years of age groups, estimated glomerular filtration rate (eGFR) was decreased significantly from baseline at months 3, 6, 9, and 12, whereas there was no significant decrease from the month-3 value at months 6, 9, or 12. Meanwhile, in the < 65 years of age group, eGFR was decreased significantly from baseline at months 9 and 12, whereas changes at months 3 and 6 were not significant. There were significant differences in the magnitude of eGFR changes among age groups at month 3, but not at months 6,9, or 12. Hemoglobin A1c (HbA1c) was reduced significantly at month 3, and the reduced level was maintained until month 12 in all age groups. Conclusions:The efficacy and safety of sitagliptin therapy in the elderly were confirmed in non-specialist settings. These findings will help non-diabetologists choose an appropriate drug in areas where the numbers of diabetic patients and elderly persons are increasing.

show abstract

Section: Efficacy Of Sitagliptin In Elderly Patientssupporting

confidence: 52%

Evaluation of Age-Specific Efficacy and Safety of 12 Months of Sitagliptin Therapy Administered by Non-Diabetologists

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a study of 940 patients, TC showed a significant decrease and serum creatinine was increased significantly by sitagliptin treatment [ 15 ]. In addition, evaluation of serum creatinine up to 2 years (n = 826) showed that the serum creatinine level was increased significantly at 1 month after the start of sitagliptin treatment, but there were no significant changes subsequently [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to reduce hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the reduction varies between patients and adequate glycemic control may not be achieved. We evaluated the efficacy and safety of the DPP-4 inhibitor alogliptin in the real clinical setting, and analyzed factors associated with the improvement of HbA1c by alogliptin treatment.MethodsA retrospective observational study was performed in patients with type 2 diabetes attending hospitals or clinics belonging to the Kanagawa Physicians Association who received treatment with alogliptin for 1 year or longer. Patients using insulin were excluded from the study. The efficacy endpoints were HbA1c (National Glycohemoglobin Standardization Program value), blood glucose (fasting/postprandial), body weight, blood pressure (systolic/diastolic), liver function (glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, and γ-glutamyl transpeptidase), kidney function (serum creatinine and estimated glomerular filtration rate), serum lipids (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and serum amylase. Adverse events were compiled to assess safety.ResultsOf 330 patients whose case records were collected, 27 patients were excluded for protocol violations, leaving 303 patients to form the full analysis set. Compared with baseline, HbA1c showed a decrease by 0.54±1.22% (mean ± standard deviation) after 12 months of alogliptin treatment. Factor analysis demonstrated that the change of HbA1c after 12 months was significantly influenced by the baseline HbA1c level, duration of diabetes, concomitant use of sulfonylureas, and compliance with diet therapy. In addition, there was a significant reduction of total cholesterol, low-density lipoprotein cholesterol, and the estimated glomerular filtration rate after 12 months of alogliptin treatment, as well as a significant increase in serum creatinine. No significant changes of body weight, blood pressure, or liver function were observed. Symptoms of hypoglycemia occurred in two patients (0.6%).ConclusionsAlogliptin displayed a significant hypoglycemic effect and excellent safety in routine clinical use. Factors influencing the change of HbA1c with alogliptin therapy may include the HbA1c at the start of treatment, the duration of diabetes, use of sulfonylureas, and compliance with diet therapy.

show abstract

“…As diabetes progresses, the risk of renal involvement increases, including potential development of diabetic nephropathy and renal failure [20]. It has been reported that DPP4 inhibitors may affect renal function, and we previously found slight elevation of creatinine, albeit within the reference range, in patients receiving sitagliptin [21]. Chao et al investigated several DPP4 inhibitors (sitagliptin, vildagliptin, and saxagliptin) in T2DM patients, and concluded that the risk of acute kidney injury was low with all of these drugs [22].…”

Section: Introductionmentioning

confidence: 55%

Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice

Matsuba¹,

Iemitsu²,

Kawata³

et al. 2019

J Endocrinol Metab

Self Cite

View full text Add to dashboard Cite

Background: Dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors are frequently used to treat type 2 diabetes. However, there have been no direct comparisons of these antidiabetic drugs in Japanese patients with type 2 diabetes. Methods: We retrospectively assessed the effects of treatment with sitagliptin (a dipeptidyl peptidase-4 inhibitor) for 24 weeks in the ASSET-K study or treatment with ipragliflozin (a sodium-glucose cotransporter-2 inhibitor) for 24 weeks in the ASSIGN-K study. In both studies, patients with poor glycemic control received the study drug in addition to standard care with/without other antidiabetic medications or were switched to the study drug. The effects of each drug on metabolic risk factors (body weight, blood glucose, and lipids), blood pressure, and renal function were compared. Results: After 4 weeks of treatment, hemoglobin A1c was significantly lower in patients receiving ipragliflozin than in those receiving sitagliptin, but the difference was not significant at 12 or 24 weeks. Body mass index showed a significantly larger decrease with ipragliflozin treatment than sitagliptin treatment throughout most of the study period (P < 0.001 at 24 weeks). The mean blood pressure also showed a significantly larger decrease with ipragliflozin treatment than sitagliptin treatment throughout most of the study period (P = 0.007 at 24 weeks). In contrast, the decrease of the estimated glomer-ular filtration rate after 24 weeks was significantly larger in patients treated with sitagliptin than those receiving ipragliflozin (P = 0.012). Conclusions: Ipragliflozin may be more effective than sitagliptin for Japanese patients with type 2 diabetes who have hypertension, obesity, and/or renal dysfunction.

show abstract

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Cited by 13 publications

References 10 publications

Evaluation of Age-Specific Efficacy and Safety of 12 Months of Sitagliptin Therapy Administered by Non-Diabetologists

Evaluation of Age-Specific Efficacy and Safety of 12 Months of Sitagliptin Therapy Administered by Non-Diabetologists

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study

Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice

Contact Info

Product

Resources

About